Factors Associated With Chemotherapy-Induced Neutropenia In Patients With Haematological Malignancies At Dr George Mukhari Academic Hospital, Pretoria, South Africa
Keywords
References
Dale DC - Understanding neutropenia. Current Opinion in Haematology, 2014; 21(1):1- 5. doi:10.1097/moh.0000000000000012.
Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H et al. - Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens. Supportive care in cancer: Journal of the Multinational Association of Supportive Care in Cancer (MASCC), 2014. doi:10.1007/s00520-014-2362-5
Gea-Banacloche J. - Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies. Hematology/the Education Program of the American Society of Hematology, 2013; 182: 414-422. doi:10.1182/asheducation-2013.1.414.
Crawford J, Dale DC, Lyman GH. - Chemotherapy-induced neutropenia: Risks, consequences and new directions for its management. Cancer, 2004; 100: 228 - 237.
Kuderer NM, Dale DC, Crawford J et al. - Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer, 2006; 106: 2258 – 2266.
Lyman GH, Michels SL, Reynolds MW et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer, 2010; 116 (23): 5555- 63.
Lyman GH, Kuderer NM. - Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs, 2002; 62(Suppl 1): 65 - 78.
Alexander SW, Pizzo PA. - Current considerations in the management of fever and neutropenia. Curr Clin Top Infect. Dis., 1999; 19: 160 - 180.
Lehrnbecher T, Chanock SJ. - Controversies in the treatment of neutropenia in cancer patients. Curr Opin Hematol, 1998; 5(1): 26 - 32.
Caggiano V, Weiss RV, Rickert TS et al. - Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer, 2005; 103 (9): 1916 - 1924.
Freifeld GA, Bow EJ, Sepkowitz KA et al. - Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis, 2011; 52: e56.
National Cancer Institute. Common toxicity criteria, version. 2.0. Available from URL: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf [access date January 3, 2014].
Hassan B.A.R, Yousoff Z.B.H, Othman S.B. - Neutropenia onset, severity and their association with Demographic Data. Asian Journal of Pharmacutical and Clinical Research, 2009; 22: 51 - 53.
Lyman GH, Delgado D.J. - Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R or CNOP chemotherapy for intermediate-grade Non-Hodgkins lymphoma. Cancer, 2003; 98: 2402 - 2409.
Lyman G.H, Wilmot J.P. - Risks and consequences of chemotherapy-induced neutropenia. Clinical Cornerstone, 2006; 8: 12 - 18.
Nakagawa Y, Suzuki K, Masaoka T. Evaluation of the risk factors for febrile neutropenia associated with haematological malignancy. J Infec Chemother 2009; 15:174- 179.
Pettengell R, Bosly A, Szucs T.D, Jackisch et al. - Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: Data from the INC-EU Prospective Observational European Neutropenia Study. Brit J Haematol, 2008; March; 144 (5): 677 – 685.